J.P. Morgan Reiterates Overweight, $27 PT On NxStage Medical

J.P. Morgan reiterated an overweight rating and $27 price target on NxStage Medical

, noting that the price target could prove conservative on the back of “quarterly execution and continued clinical evidence.” The bank also forecast a 2012 loss of 15 cents a share for NxStage compared with a previous estimate of a loss of 6 cents a share. J.P. Morgan expects quarterly losses of $0.07, $0.04, $0.02 and $0.02, respectively, from NxStage.